Fig. 7.
Fig. 7. (A) PCR products obtained using as template cDNA prepared from untreated or anti-CD3–treated mouse spleen cells. Line 1, untreated spleen cells; line 2, spleen cells incubated overnight with anti-CD3 MoAb (1 μg/mL); line 3, negative control. The primers 1 (forward) and 2 (reverse) are shown in Fig 2B. RNase protection analysis of FasL and FasLs mRNA expression from nonactivated and anti-CD3–activated spleen cells. Each line was loaded with 30 μg of total RNA. Line 1, undigested probe; line 2, tRNA; line 3, nonactivated spleen cells; line 4, activated spleen cells.

(A) PCR products obtained using as template cDNA prepared from untreated or anti-CD3–treated mouse spleen cells. Line 1, untreated spleen cells; line 2, spleen cells incubated overnight with anti-CD3 MoAb (1 μg/mL); line 3, negative control. The primers 1 (forward) and 2 (reverse) are shown in Fig 2B. RNase protection analysis of FasL and FasLs mRNA expression from nonactivated and anti-CD3–activated spleen cells. Each line was loaded with 30 μg of total RNA. Line 1, undigested probe; line 2, tRNA; line 3, nonactivated spleen cells; line 4, activated spleen cells.

Close Modal

or Create an Account

Close Modal
Close Modal